-+ 0.00%
-+ 0.00%
-+ 0.00%

Purple Biotech Q3 Net Loss Narrows 25% to USD 981,000

PUBT·11/17/2026 12:55:49
Listen to the news
Purple Biotech Q3 Net Loss Narrows 25% to USD 981,000
  • Purple Biotech’s third-quarter 2026 net loss narrowed 25% year-over-year to USD 981,000.
  • Research and development expenses fell 38% year-over-year to USD 364,000, primarily due to lower manufacturing-related and patent expenses.
  • Cash, cash equivalents and short-term deposits totaled USD 5.1 million at September 30, 2026, with projected runway through late 2027.
  • An investigational new drug application for IM1240 is planned during 2027, followed by a first-in-human study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Purple Biotech Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611170755PRIMZONEFULLFEED9879364) on November 17, 2026, and is solely responsible for the information contained therein.